Loading…

Protocol - Pre-transfusion Antibody Testing

Add to My Toolkit
Description

This protocol includes two items from the Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange Trial (SCD CARRE) that use existing medical records to capture the results of a red blood cell (RBC) antibody screen and direct antiglobulin test (DAT).

Specific Instructions

None

Protocol

Test Name

Result

Date of sample

(If different from above)

dd-mon-yy

Not Done

Comments

Antibody Tests

1 RBC Antibody Screen

[ ] Negative

[ ] Positive

__-__-__

[ ]

[ ] Rh D

   Rh C

 Rh c

[ ] Rh E

[ ] Rh e

[ ] Kell

[ ] Fya

[ ] Fyb

[ ] Jka

[ ] Jkb

[ ] S

[ ] s

[ ] Other____

2 Direct Antiglobulin

[ ] Negative

[ ] Positive

__-__-__

[ ]

Polyspecific

[ ] -

              

[ ] + w-4+

IgG

[ ] -

              

[ ] + w-4+

C3

[ ] -

              

[ ] + w-4+

Availability

Available

Personnel and Training Required

This information should be abstracted by someone conversant in hematology.

Equipment Needs

None

Requirements
Requirement CategoryRequired
Major equipment No
Specialized training No
Specialized requirements for biospecimen collection No
Average time of greater than 15 minutes in an unaffected individual No
Mode of Administration

Medical record abstraction

Lifestage

Adult

Participants

This form is to be completed by designated personnel for all adverse transfusion reactions.

Selection Rationale

The Sickle Cell Disease Curative Therapies Working Group selected questions from the Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange (SCD-CARRE) as the best standardized methodology for collecting data on pre-transfusion antibody testing. 

Language

English

Standards
StandardNameIDSource
caDSR Common Data Elements (CDE) Laboratory Procedure Red Blood Cell Antibody Test Result 7765231 CDE Browser
caDSR Common Data Elements (CDE) Laboratory Procedure Direct Antiglobulin Antibody Test Result 7765235 CDE Browser
Derived Variables

None

Process and Review

N/A

Protocol Name from Source

Sickle Cell Disease and Cardiovascular Risk—Red Cell Exchange Trial (SCD CARRE)

Source

National Heart, Lung, and Blood Institute. (2020). Sickle Cell Disease and CardiovAscular Risk—Red Cell Exchange (Version 1.0) [Laboratory evaluation].

General References

Chou, S T., Alsawas, M., Fasano, R. M., Field, J. J., Hendrickson, J. E., Howard, J., Kameka, M., Kwiatkowski, J. L., Pirenne, F., Shi, P. A., Stowell, S. R., Thein, S. L., Westhoff, C. M., Wong, T. E., & Akl, E. A. (2020). American Society of Hematology 2020 guidelines for sickle cell disease: Transfusion support. Blood Advances, 4(2), 327–355.

Protocol ID

850901

Variables
Export Variables
Variable Name Variable IDVariable DescriptiondbGaP Mapping
Blood Sciences Research
Measure Name

Pre-transfusion Antibody Reporting

Release Date

August 16, 2021

Definition

This measure is used to record the presence or absence of red cell antibodies.

Purpose

The transfusion recipient can mount an immune response to donor red blood cells, which can result in a hemolytic transfusion reaction, shock, kidney failure, circulatory system collapse, and death.

Keywords

Sickle cell disease, SCD, transfusion, antibody, direct antiglobulin test, DAT

Measure Protocols
Protocol ID Protocol Name
850901 Pre-transfusion Antibody Testing
Publications

There are no publications listed for this protocol.